OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press747HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯGuidelines of Russian Expert Council on diagnostic and therapy of patients with primary immunne thrombocytopeniaРекомендации Российского Совета экспертов по диагностике и лечению больных первичной иммунной тромбоцитопениейMaschanA. A.МасчанА. А.
Russian Federation

Moscow

Алексей Александрович Масчан

ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии

Москва

amaschan@mail.ruRumyantsevA. G.РумянцевА. Г.
Russian Federation

Moscow

ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии

Москва

KovalevaL. G.КовалеваЛ. Г.
Russian Federation

Russian Hematological Scientific Center

Moscow

Гематологический научный центр

Москва

AfanasievB. V.АфанасьевБ. В.
Russian Federation

Raisa Gorbacheva Memorial Institute of Pediatric Hematology and Transplantology

St-Petersburg

Институт детской гематологии и трансплантологии

Санкт-Петербург

PospelovaT. I.ПоспеловаТ. И.
Russian Federation

Novosibirsk

кафедра терапии, гематологии и трансфузиологии

Новосибирск

ZaritskiyA. Yu.ЗарицкийА. Ю.
Russian Federation

St-Petersburg

Санкт-Петербург

AbdulkadyrovK. M.АбдулкадыровК. М.
Russian Federation

St.-Petersburg

Санкт-Петербург

PtushkinV. V.ПтушкинВ. В.
Russian Federation

Moscow

ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии

Москва

TsvetaevaN. V.ЦветаеваН. В.
Russian Federation

Russian Hematological Scientific Center

Moscow

Гематологический научный центр

Москва

LisukovI. A.ЛисуковИ. А.
Russian Federation

Raisa Gorbacheva Memorial Institute of Pediatric Hematology and Transplantology

St-Petersburg

Институт детской гематологии и трансплантологии

Санкт-Петербург

SalogubG. N.СалогубГ. Н.
Russian Federation

St.-Petersburg

Санкт-Петербург

GolenkovA. K.ГоленковА. К.
Russian Federation

Moscow

Москва

MedvedevaN. V.МедведеваН. В.
Russian Federation

St.-Petersburg

Санкт-Петербург

RukavitsynO. A.РукавицынО. А.
Russian Federation

Moscow

Москва

IvanovaV. L.ИвановаВ. Л.
Russian Federation

Moscow

Москва

MarkovaI. V.МарковаИ. В.
Russian Federation

Raisa Gorbacheva Memorial Institute of Pediatric Hematology and Transplantology

St-Petersburg

Институт детской гематологии и трансплантологии

Санкт-Петербург

Federal Research Center of Pediatric Hematology, Oncology and ImmunologyМинздравсоцразвития РоссииRAMSРАМНSt.-Petersburg State Pavlov Medical UniversityСанкт-Петербургский государственный медицинский университет им. И. П. ПавловаNovosibirsk State Medical UniversityНовосибирский государственный медицинский университетAlmazov Federal Heart, Blood and Endocrinology CentreФедеральный Центр сердца, крови и эндокринологии им. В. А. АлмазоваRussian Research Institute of Hematology and TransfusiologyРоссийский НИИ гематологии и трансфузиологииM.F. Vladimirsky Moscow Regional Research Clinical InstituteМосковский областной научно-исследовательский клинический институт им. М. Ф. ВладимирскогоMunicipal Clinical Hospital № 31ГКБ № 31N. N. Burdenko Main Military Clinical HospitalГлавный военный клинический госпиталь им. акад. Н. Н. БурденкоMunicipal Hematological CenterГородской гематологический центр при ГКБ им. С. П. Боткина260820103364525112022251120222010https://oncohematology.abvpress.ru/ongm/article/view/747

   New guidelines on diagnosis and treatment of a primary immune thrombocytopenia (ITP) in children and adults, on the basis of modern pathogenesis conceptions and considering possibilities of hematological practice in Russia are presented. Guidelines are based on a consensus of international and Russian experts on ITP. Diagnostic features of ITP are noted and various I, II and III lines treatment, including new effective medical products which have recently appeared in Russia, in particular, trombopoietin receptor agonists (romiplostim, eltrombopag), considerably expanded conservative treatment possibilities are offered. The presented guidelines can help hematologists to develop individual schedule for each given patients with ITP and to improve patients quality of life.

   Представлены новые рекомендации по диагностике и лечению первичной иммунной тромбоцитопении (ИТП) у взрослых и детей, разработанные на основе современных знаний о патогенезе заболевания и учитывающие возможности гематологической практики в России. Рекомендации основаны на согласованном мнении ведущих международных и российских экспертов по ИТП. Отмечены особенности диагностики ИТП и предложены различные варианты лечения 1, 2 и 3-й линий, включающие новые эффективные лекарственные препараты, недавно появившиеся на российском рынке, в частности, агонисты тромбопоэтиновых рецепторов (ромиплостим, элтромбопаг), значительно расширившие возможности консервативного лечения заболевания. Представленные рекомендации могут помочь специалистам-гематологам выработать индивидуальную тактику ведения каждого конкретного больного ИТП и улучшить качество жизни пациентов.

immune thrombocytopeniaITPterminologytreatmentTPO-agonistsиммунная тромбоцитопенияИТПтерминологиятерапияагонисты рецептора тромбопоэтина1. Aledort L. M., Hayward C. P., Chen M. G., Nichol J. L., Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76 (3): 205–13.Aledort L. M., Hayward C. P., Chen M. G., Nichol J. L., Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76 (3): 205–13.2. Alpdogan O., Budak-Alpdogan T., Ratip S. et al. Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. Br J Haematol 1998; 103 (4): 1061–3.Alpdogan O., Budak-Alpdogan T., Ratip S. et al. Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. Br J Haematol 1998; 103 (4): 1061–3.3. Andersen J. C. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 30 (22): 1560–4.Andersen J. C. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 30 (22): 1560–4.4. Balmer P., Falconer M., McDonald P. et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun 2004; 72 (1): 332–7.Balmer P., Falconer M., McDonald P. et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun 2004; 72 (1): 332–7.5. Ben-Yehuda D., Gillis S., Eldor A. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol 1994; 91 (1): 1–6.Ben-Yehuda D., Gillis S., Eldor A. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol 1994; 91 (1): 1–6.6. Boruchov D. M., Gururangan S., Driscoll M. C., Bussel J. B. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007; 110 (10): 3526–31Boruchov D. M., Gururangan S., Driscoll M. C., Bussel J. B. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007; 110 (10): 3526–317. Brighton T. A., Evans S., Castaldi P. A., Chesterman C. N., Chong B. H. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996; 88 (1): 194–201.Brighton T. A., Evans S., Castaldi P. A., Chesterman C. N., Chong B. H. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996; 88 (1): 194–201.8. Bussel J. Intravenous immune serum globulin in immune thrombocytopenia: clinical results and biochemical evaluation. Vox Sang 1985; 49 (Suppl 1): 44–50.Bussel J. Intravenous immune serum globulin in immune thrombocytopenia: clinical results and biochemical evaluation. Vox Sang 1985; 49 (Suppl 1): 44–50.9. Bussel J. B. Autoimmune thrombocytopenic purpura. Hematol Oncol Clin North Am 1990; 4 (1): 179–91.Bussel J. B. Autoimmune thrombocytopenic purpura. Hematol Oncol Clin North Am 1990; 4 (1): 179–91.10. Bussel J. B., Cheng G., Saleh M. N. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357 (22): 2237–47.Bussel J. B., Cheng G., Saleh M. N. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357 (22): 2237–47.11. Bussel J. B., Kuter D. J., George J. N. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355 (16): 1672–81.Bussel J. B., Kuter D. J., George J. N. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355 (16): 1672–81.12. Bussel J. B., Kuter D. J., Pullarkat V. et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113 (10): 2161–71.Bussel J. B., Kuter D. J., Pullarkat V. et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113 (10): 2161–71.13. Bussel J. B., Provan D., Shamsi T. et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373 (9664): 641–8.Bussel J. B., Provan D., Shamsi T. et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373 (9664): 641–8.14. Cayco A. V., Perazella M. A., Hayslett J. P. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997; 8 (11): 1788–94.Cayco A. V., Perazella M. A., Hayslett J. P. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997; 8 (11): 1788–94.15. Center for Disease Control. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immunoglobulins in persons with altered immunocompetence. MMWR 1993; 42 (RR-4): 1–18.Center for Disease Control. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immunoglobulins in persons with altered immunocompetence. MMWR 1993; 42 (RR-4): 1–18.16. Cohen Y. C., Djulbegovic B., Shamai-Lubovitz O., Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160 (11): 1630–8.Cohen Y. C., Djulbegovic B., Shamai-Lubovitz O., Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160 (11): 1630–8.17. Cortelazzo S., Finazzi G., Buelli M. et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77 (1): 31–3.Cortelazzo S., Finazzi G., Buelli M. et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77 (1): 31–3.18. Cunningham-Rundles C., Knight A. K. Common variable immune deficiency: reviews, continued puzzles, and a new registry. Immunol Res 2007; 38 (1–3): 78–86.Cunningham-Rundles C., Knight A. K. Common variable immune deficiency: reviews, continued puzzles, and a new registry. Immunol Res 2007; 38 (1–3): 78–86.19. de Montalembert M., Lenoir G. Antibiotic prevention of pneumococcal infections in asplenic hosts: admission of insufficiency. Ann Hematol 2004; 83 (1): 18–21.de Montalembert M., Lenoir G. Antibiotic prevention of pneumococcal infections in asplenic hosts: admission of insufficiency. Ann Hematol 2004; 83 (1): 18–21.20. Figueroa M., Gehlsen J., Hammond D. et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993; 328 (17): 1226–9.Figueroa M., Gehlsen J., Hammond D. et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993; 328 (17): 1226–9.21. George J. N., el-Harake M. A., Raskob G. E. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994; 331 (18): 1207–11.George J. N., el-Harake M. A., Raskob G. E. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994; 331 (18): 1207–11.22. George J. N., Woolf S. H., Raskob G. E. et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88 (1): 3–40.George J. N., Woolf S. H., Raskob G. E. et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88 (1): 3–40.23. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120 (4): 574–96.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120 (4): 574–96.24. Houwerzijl E. J., Blom N. R., van der Want J. J. et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103 (2): 500–6.Houwerzijl E. J., Blom N. R., van der Want J. J. et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103 (2): 500–6.25. Jenkins J. M., Williams D., Deng Y. et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109 (11): 4739–41.Jenkins J. M., Williams D., Deng Y. et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109 (11): 4739–41.26. Johansson E., Engervall P., Landgren O. et al. Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura. Eur J Haematol 2006; 77 (1): 61–6.Johansson E., Engervall P., Landgren O. et al. Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura. Eur J Haematol 2006; 77 (1): 61–6.27. Jubelirer S. J., Harpold R. The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost 2002; 8 (1): 73–6.Jubelirer S. J., Harpold R. The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost 2002; 8 (1): 73–6.28. Kaplinsky C., Spirer Z. Post-splenectomy antibiotic prophylaxis–unfinished story: to treat or not to treat? Pediatr Blood Cancer 2006; 47 (Suppl 5): 740–1.Kaplinsky C., Spirer Z. Post-splenectomy antibiotic prophylaxis–unfinished story: to treat or not to treat? Pediatr Blood Cancer 2006; 47 (Suppl 5): 740–1.29. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995; 74 (1): 521–5.Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995; 74 (1): 521–5.30. Keidar A., Sagi B., Szold A. Laparoscopic splenectomy for immune thrombocytopenic purpura in patients with severe refractory thrombocytopenia. Pathophysiol Haemost Thromb 2003; 33 (2): 116–9.Keidar A., Sagi B., Szold A. Laparoscopic splenectomy for immune thrombocytopenic purpura in patients with severe refractory thrombocytopenia. Pathophysiol Haemost Thromb 2003; 33 (2): 116–9.31. Kitchens C. S., Weiss L. Ultrastructural changes of endothelium associated with thrombocytopenia. Blood 1975; 46 (4): 567–78.Kitchens C. S., Weiss L. Ultrastructural changes of endothelium associated with thrombocytopenia. Blood 1975; 46 (4): 567–78.32. Kitchens C. S. Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. J Clin Invest 1977; 60 (5): 1129–34.Kitchens C. S. Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. J Clin Invest 1977; 60 (5): 1129–34.33. Kojouri K., Vesely S. K., Terrell D. R., George J. N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104 (9): 2623–34.Kojouri K., Vesely S. K., Terrell D. R., George J. N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104 (9): 2623–34.34. Kumagai Y., Fujita T., Ozaki M. et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebocontrolled study. J Clin Pharmacol 2007; 47 (12): 1489–97.Kumagai Y., Fujita T., Ozaki M. et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebocontrolled study. J Clin Pharmacol 2007; 47 (12): 1489–97.35. Kuter D. J. New thrombopoietic growth factors. Blood 2007; 109 (11): 4607–16.Kuter D. J. New thrombopoietic growth factors. Blood 2007; 109 (11): 4607–16.36. Kuter D. et al. Evaluation of efficacy and safety of long-term romiplostim treatment for patients with immune thrombocytopenia (ITP) enrolled in an open-label extension study: A patient cohort-analysis. EHA 2010: Abstract № 0189.Kuter D. et al. Evaluation of efficacy and safety of long-term romiplostim treatment for patients with immune thrombocytopenia (ITP) enrolled in an open-label extension study: A patient cohort-analysis. EHA 2010: Abstract № 0189.37. Kuter D. J., Bussel J. B., Lyons R. M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371 (9610): 395–403.Kuter D. J., Bussel J. B., Lyons R. M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371 (9610): 395–403.38. Liebman H. Other immune thrombocytopenias. Semin Hematol 2007; 44 (4 Suppl 5): 24–34.Liebman H. Other immune thrombocytopenias. Semin Hematol 2007; 44 (4 Suppl 5): 24–34.39. Liebman H. A., Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol 2007; 14 (5): 557–73.Liebman H. A., Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol 2007; 14 (5): 557–73.40. Mak Y. K., Yu P. H., Chan C. H., Chu Y. C. The management of isolated thrombocytopenia in Chinese adults: does bone marrow examination have a role at presentation? Clin Lab Haematol 2000; 22 (6): 355–8.Mak Y. K., Yu P. H., Chan C. H., Chu Y. C. The management of isolated thrombocytopenia in Chinese adults: does bone marrow examination have a role at presentation? Clin Lab Haematol 2000; 22 (6): 355–8.41. Makris M., Greaves M., Winfield D. A., Preston F. E., Lilleyman J. S. Long-term management after splenectomy. Lifelong penicillin unproved in trials. BMJ 1994; 308 (6921): 131–2.Makris M., Greaves M., Winfield D. A., Preston F. E., Lilleyman J. S. Long-term management after splenectomy. Lifelong penicillin unproved in trials. BMJ 1994; 308 (6921): 131–2.42. Mathias S. D., Bussel J. B., George J. N. et al. A disease- specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007; 5: 11.Mathias S. D., Bussel J. B., George J. N. et al. A disease- specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007; 5: 11.43. Mathias S. D., Gao S. K., Miller K. L. et al. Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 2008; 6: 13.Mathias S. D., Gao S. K., Miller K. L. et al. Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 2008; 6: 13.44. Mazzucconi M. G., Fazi P., Bernasconi S. et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109 (4): 1401–7.Mazzucconi M. G., Fazi P., Bernasconi S. et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109 (4): 1401–7.45. McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981; 304 (19): 1135–47.McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981; 304 (19): 1135–47.46. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med 2001; 344 (18): 1402–3.McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med 2001; 344 (18): 1402–3.47. McMillan R., Bussel J. B., George J. N., Lalla D., Nichol J. L. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008; 83 (2): 150–4.McMillan R., Bussel J. B., George J. N., Lalla D., Nichol J. L. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008; 83 (2): 150–4.48. McMillan R., Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004; 104 (4): 956–60.McMillan R., Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004; 104 (4): 956–60.49. McMillan R., Wang L., Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003; 1 (3): 485–91.McMillan R., Wang L., Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003; 1 (3): 485–91.50. McMullin M., Johnston G. Long term management of patients after splenectomy. BMJ 1993; 307 (6916): 1372–3.McMullin M., Johnston G. Long term management of patients after splenectomy. BMJ 1993; 307 (6916): 1372–3.51. Mittal S., Blaylock M. G., Culligan D. J., Barker R. N., Vickers M. A. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica 2008; 93 (1): 151–2.Mittal S., Blaylock M. G., Culligan D. J., Barker R. N., Vickers M. A. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica 2008; 93 (1): 151–2.52. Naouri A., Feghali B., Chabal J. et al. Results of splenectomy for idiopathic thrombocytopenic purpura. Review of 72 cases. Acta Haematol 1993; 89 (4): 200–3.Naouri A., Feghali B., Chabal J. et al. Results of splenectomy for idiopathic thrombocytopenic purpura. Review of 72 cases. Acta Haematol 1993; 89 (4): 200–3.53. Newland A. C., Treleaven J. G., Minchinton R. M., Waters H. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983; 1 (8316): 84–7.Newland A. C., Treleaven J. G., Minchinton R. M., Waters H. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983; 1 (8316): 84–7.54. Newland A., Caulier M. T., Kappers-Klunne M. et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135 (4): 547–553.Newland A., Caulier M. T., Kappers-Klunne M. et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135 (4): 547–553.55. Newland A., Provan D., Myint S. Preventing severe infection after splenectomy. BMJ 2005; 331 (7514): 417–8.Newland A., Provan D., Myint S. Preventing severe infection after splenectomy. BMJ 2005; 331 (7514): 417–8.56. Neylon A. J., Saunders P. W., Howard M. R., Proctor S. J., Taylor P. R. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122 (6): 966–74.Neylon A. J., Saunders P. W., Howard M. R., Proctor S. J., Taylor P. R. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122 (6): 966–74.57. Pizzuto J., Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984; 64 (6): 1179–83.Pizzuto J., Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984; 64 (6): 1179–83.58. Portielje J. E., Westendorp R. G., Kluin-Nelemans H. C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97 (9): 2549–54.Portielje J. E., Westendorp R. G., Kluin-Nelemans H. C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97 (9): 2549–54.59. Provan D., Stasi R., Newland A., Blanchette V., Bolton-Maggs P. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (2): 168–186.Provan D., Stasi R., Newland A., Blanchette V., Bolton-Maggs P. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (2): 168–186.60. Psaila B., Bussel J. B. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 2008; 143 (1): 16–26.Psaila B., Bussel J. B. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 2008; 143 (1): 16–26.61. Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11): 2386–93.Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11): 2386–93.62. Schiavotto C., Ruggeri M., Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78 (6 Suppl 2): 35–40.Schiavotto C., Ruggeri M., Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78 (6 Suppl 2): 35–40.63. Schwartz J., Leber M. D., Gillis S. et al. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003; 72 (2): 94–8.Schwartz J., Leber M. D., Gillis S. et al. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003; 72 (2): 94–8.64. Segal J. B., Powe N. R. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4 (11): 2377–83.Segal J. B., Powe N. R. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4 (11): 2377–83.65. Stasi R., Brunetti M., Pagano A. et al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 2000; 26 (6): 582–6.Stasi R., Brunetti M., Pagano A. et al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 2000; 26 (6): 582–6.66. Stasi R., Evangelista M. L., Stipa E. et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99 (1): 4–13.Stasi R., Evangelista M. L., Stipa E. et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99 (1): 4–13.67. Stasi R., Sarpatwari A., Segal J. B. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood 2009; 113 (6): 1231–40.Stasi R., Sarpatwari A., Segal J. B. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood 2009; 113 (6): 1231–40.68. Stasi R., Stipa E., Masi M. et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98 (5): 436–42.Stasi R., Stipa E., Masi M. et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98 (5): 436–42.69. Stasi R., Stipa E., Masi M. et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84 (12): 4203–8.Stasi R., Stipa E., Masi M. et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84 (12): 4203–8.70. Vianelli N., Galli M., de Vivo A. et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90 (1): 72–7.Vianelli N., Galli M., de Vivo A. et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90 (1): 72–7.71. Von dem Borne A. E., Vos J. J., Pegels J. G., Thomas L. L., van der Lelie. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed) 1988; 296 (6617): 249–50.Von dem Borne A. E., Vos J. J., Pegels J. G., Thomas L. L., van der Lelie. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed) 1988; 296 (6617): 249–50.72. Yang R., Han Z. C. Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: an update. Int J Hematol 2000; 71 (1): 18–24.Yang R., Han Z. C. Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: an update. Int J Hematol 2000; 71 (1): 18–24.